Arcus Biosciences (RCUS) Competitors $9.26 +0.23 (+2.56%) Closing price 03:59 PM EasternExtended Trading$9.26 -0.01 (-0.06%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCUS vs. RNA, PTCT, ACLX, MRUS, ZLAB, SRRK, ACAD, VKTX, SWTX, and PTGXShould you be buying Arcus Biosciences stock or one of its competitors? The main competitors of Arcus Biosciences include Avidity Biosciences (RNA), PTC Therapeutics (PTCT), Arcellx (ACLX), Merus (MRUS), Zai Lab (ZLAB), Scholar Rock (SRRK), ACADIA Pharmaceuticals (ACAD), Viking Therapeutics (VKTX), SpringWorks Therapeutics (SWTX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry. Arcus Biosciences vs. Its Competitors Avidity Biosciences PTC Therapeutics Arcellx Merus Zai Lab Scholar Rock ACADIA Pharmaceuticals Viking Therapeutics SpringWorks Therapeutics Protagonist Therapeutics Arcus Biosciences (NYSE:RCUS) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk. Does the media refer more to RCUS or RNA? In the previous week, Avidity Biosciences had 2 more articles in the media than Arcus Biosciences. MarketBeat recorded 9 mentions for Avidity Biosciences and 7 mentions for Arcus Biosciences. Avidity Biosciences' average media sentiment score of 0.84 beat Arcus Biosciences' score of -0.12 indicating that Avidity Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Avidity Biosciences 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RCUS or RNA? Arcus Biosciences has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Do institutionals & insiders believe in RCUS or RNA? 92.9% of Arcus Biosciences shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer RCUS or RNA? Arcus Biosciences presently has a consensus price target of $21.29, indicating a potential upside of 129.84%. Avidity Biosciences has a consensus price target of $66.35, indicating a potential upside of 97.89%. Given Arcus Biosciences' higher probable upside, equities research analysts plainly believe Arcus Biosciences is more favorable than Avidity Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arcus Biosciences 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 1 Strong Buy rating(s) 3.06 Which has preferable earnings & valuation, RCUS or RNA? Arcus Biosciences has higher revenue and earnings than Avidity Biosciences. Avidity Biosciences is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArcus Biosciences$258M3.80-$283M-$4.19-2.21Avidity Biosciences$10.90M370.74-$322.30M-$3.00-11.18 Is RCUS or RNA more profitable? Arcus Biosciences has a net margin of -258.94% compared to Avidity Biosciences' net margin of -4,136.00%. Avidity Biosciences' return on equity of -26.96% beat Arcus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Arcus Biosciences-258.94% -70.58% -32.97% Avidity Biosciences -4,136.00%-26.96%-24.57% SummaryAvidity Biosciences beats Arcus Biosciences on 9 of the 16 factors compared between the two stocks. Get Arcus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RCUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCUS vs. The Competition Export to ExcelMetricArcus BiosciencesMED IndustryMedical SectorNYSE ExchangeMarket Cap$956.14M$2.91B$5.52B$20.63BDividend YieldN/A2.46%4.25%3.68%P/E Ratio-2.2120.3628.1527.27Price / Sales3.80302.56437.6355.15Price / CashN/A42.3835.5321.88Price / Book1.757.768.234.60Net Income-$283M-$55.11M$3.23B$995.22M7 Day Performance-0.53%0.95%-0.01%-0.80%1 Month Performance1.97%8.44%5.61%3.55%1 Year Performance-41.72%-2.38%26.52%7.35% Arcus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCUSArcus Biosciences2.3103 of 5 stars$9.26+2.6%$21.29+129.8%-41.5%$956.14M$258M-2.21500RNAAvidity Biosciences2.3305 of 5 stars$33.57+6.7%$66.35+97.7%-30.5%$4.05B$8.93M-11.19190Gap UpHigh Trading VolumePTCTPTC Therapeutics4.384 of 5 stars$49.46+1.9%$65.00+31.4%+44.1%$3.92B$806.78M7.601,410Analyst RevisionACLXArcellx2.4906 of 5 stars$69.92+1.4%$111.23+59.1%+7.6%$3.85B$76.81M-23.3880News CoveragePositive NewsMRUSMerus1.9238 of 5 stars$55.62+2.1%$84.64+52.2%-5.4%$3.85B$36.13M-13.6337News CoverageZLABZai Lab3.2894 of 5 stars$34.28+4.7%$54.28+58.3%+95.5%$3.81B$398.99M-13.771,869SRRKScholar Rock3.0717 of 5 stars$38.59+3.1%$42.67+10.6%+320.8%$3.66B$33.19M-15.25140ACADACADIA Pharmaceuticals4.0819 of 5 stars$21.89+4.3%$27.88+27.3%+22.1%$3.66B$957.80M15.98510Analyst RevisionVKTXViking Therapeutics4.6176 of 5 stars$31.63+1.7%$87.15+175.5%-48.3%$3.55BN/A-27.5020Positive NewsUpcoming EarningsGap UpSWTXSpringWorks Therapeutics1.5998 of 5 stars$46.99flat$52.57+11.9%N/A$3.54B$191.59M-13.78230Positive NewsPTGXProtagonist Therapeutics1.448 of 5 stars$55.23+4.2%$66.10+19.7%+50.5%$3.42B$434.43M73.64120Positive News Related Companies and Tools Related Companies Avidity Biosciences Competitors PTC Therapeutics Competitors Arcellx Competitors Merus Competitors Zai Lab Competitors Scholar Rock Competitors ACADIA Pharmaceuticals Competitors Viking Therapeutics Competitors SpringWorks Therapeutics Competitors Protagonist Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:RCUS) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredTrump has to finance $21 trillion. Here’s His Move…Trump needs $21 trillion to fund his agenda — and insiders believe he’s quietly preparing a major shift in the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
